Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy

Title: Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy

Volume: 15 Issue: 21

Author(s): Andrea Tinelli, Roberta Martignago, Daniele Vergara, Giuseppe Leo, Antonio Malvasi and Raffaele Tinelli

Affiliation:

Keywords: Endometriosis, genomics, proteomics, GnRH agonists, angiogenesis, aromatase inhibitors, immune system, nonhormonal treatments, genetical predisposition

Abstract: Background: Endometriosis is an estrogen-dependent disease, associated with pelvic pain and infertility, with still limited knowledge of the pathogenesis, pathophysiology of related infertility and evolution. Objective: To investigate proteogenomic approaches and new trends of endometriosis treatment. Methods: A literature search was carried out for all articles on endometriosis related to immune system, and to nonhormonal, antiangiogenic and experimental therapies. Results/Conclusions: Classic endometriosis pharmacotherapy is represented by GnRH agonists, oral contraceptives and Type II progesterone receptor ligands. New proteomic and genomic technologies could help to clarify the aetiology of endometriosis and promise the rapid identification of a new generation of drugs with a specific molecular target, with the aim to ameliorate the patients quality of life.

Cite this article as:

Tinelli Andrea, Martignago Roberta, Vergara Daniele, Leo Giuseppe, Malvasi Antonio and Tinelli Raffaele, Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy, Current Medicinal Chemistry 2008; 15 (21) . https://dx.doi.org/10.2174/092986708785747571